Full X-TOLE2 Data Detail Azetukalner's Dose-Dependent Profile in Focal Epilepsy

Author profile image Aggregator
0 comments
Peer-reviewed results from the phase 3 X-TOLE2 trial, published in JAMA Neurology, detail azetukalner's seizure reduction and dose-dependent adverse events in adults with focal epilepsy.

Source: NeurologyLive Published 17 Nov 2026 Imported 17 Nov 2026 Relevancy: Not reviewed

Read the article